Evotec SE (EVO) Gains from Investment Securities (2022 - 2025)
Evotec SE (EVO) reported Gains from Investment Securities of -$2.5 million for Q4 2025, down 105.9% on a YoY basis from $42.3 million in Q4 2024, and down 162666.34% sequentially from $1533.8 in Q3 2025.
Evotec SE (EVO) Gains from Investment Securities (2022 - 2025) Analysis & Trends
Evotec SE (EVO) has 4 years of Gains from Investment Securities data on file, last reported at -$2.5 million in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities fell 105.9% year-over-year to -$2.5 million; the trailing twelve-month figure through Dec 2025 stood at $39.8 million (down 23.71% YoY), and the FY2025 full-year result was -$2.5 million, down 105.9% from the prior year.
- Gains from Investment Securities eased to -$2.5 million in Q4 2025, from $1533.8 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $175.5 million in Q4 2022 to a low of -$2.5 million in Q4 2025.
- A 4-year average of $22.5 million and a median of $13443.8 in 2023 frame the typical range for Gains from Investment Securities.
- Peak annual rise in Gains from Investment Securities reached 329.22% in 2024, while the deepest fall reached 137.81% in 2024.
- Tracing EVO's Gains from Investment Securities over 4 years: stood at $175.5 million in 2022, then tumbled by 94.39% to $9.8 million in 2023, then jumped by 329.22% to $42.3 million in 2024, then sank by 105.9% to -$2.5 million in 2025.
- Business Quant data shows EVO's Gains from Investment Securities at -$2.5 million in Q4 2025, $1533.8 in Q3 2025, and $42.3 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.82 Bn | 87.96 Bn | - |
| 2 | Teva Pharmaceutical Industries | 36.03 Bn | 32.29 Bn | 1.97 Bn |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.50 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.02 Bn | 20.86 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.43 Bn | 18.63 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.46 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.73 Bn | 12.30 Bn | 785.00 Mn |
| 10 | Evotec SE | 341.84 Mn | 341.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.49 Mn |
| Dec 31, 2025 | -2.49 Mn |
| Sep 30, 2025 | 1,533.80 |
| Sep 30, 2025 | 1,533.80 |
| Dec 31, 2024 | 42.27 Mn |
| Dec 31, 2024 | 42.27 Mn |
| Sep 30, 2024 | -6,845.20 |
| Sep 30, 2024 | -6,845.20 |
| Dec 31, 2023 | 9.85 Mn |
| Dec 31, 2023 | 9.85 Mn |
| Sep 30, 2023 | 18,105.44 |
| Sep 30, 2023 | 18,105.44 |
| Jun 30, 2023 | 8,782.18 |
| Jun 30, 2023 | 8,782.18 |
| Dec 31, 2022 | 175.52 Mn |
| Dec 31, 2022 | 175.52 Mn |
| Sep 30, 2022 | 29,179.46 |
| Sep 30, 2022 | 29,179.46 |
| Jun 30, 2022 | -67,015.43 |
| Jun 30, 2022 | -67,015.43 |